Issue 3 16 January 2004 Page 1 / 5



# sCD138 (Syndecan-1) ELISA KIT

#### **INTENDED USE**

The Human sCD138 ELISA is to be used for the in-vitro quantitative determination of soluble Syndecan-1 molecule (sCD138) in human serum, plasma, buffered solutions or cell culture medium. This kit has been configured for research use only and is not to be used in diagnostic procedures.

Note: In previous sCD138 ELISA kits, standard range values were given in units/ml. These units have now been quantified and 1000U equals 256 ng of sCD138.

# PRINCIPLE OF THE METHOD

The sCD138 Kit is a solid phase sandwich <u>Enzyme Linked-Immuno-Sorbent Assay</u> (ELISA). A monoclonal antibody specific for sCD138 has been coated onto the wells of the microtiter strips provided. Samples, including standards of known sCD138 concentrations, specimens and unknowns are pipetted into these wells.

During the first incubation, the sCD138 antigen and a biotinylated monoclonal antibody specific for CD138 are simultaneously incubated. After washing, the enzyme ( streptavidin-peroxydase ) is added. After incubation and washing to remove all the unbound enzyme, a substrate solution which is acting on the bound enzyme is added to induce a coloured reaction product. The intensity of this coloured product is directly proportional to the concentration of sCD138 present in the samples.

## REAGENTS PROVIDED AND RECONSTITUTION

| REAGENTS (Store at 2-8°c) COLOUR CO |                     | 1x96 wells<br>Cat # 850.640.096 | 2x96 wells<br>Cat # 850.640.192 | RECONSTITUTION   |  |  |  |
|-------------------------------------|---------------------|---------------------------------|---------------------------------|--|--|--|--|
| 96-wells microtiter plates          |                     | 1                               | 2                               | Ready-to-use   |  |  |  |
| Plastic cover                       |                     | 2                               | 4                               |  |  |  |  |
| Standard : 256 ng/ml                | Yellow              | 2 vials                         | 4 vials                         | Reconstitute with the volume of standard diluent indicated on the vial. (See Reagents Preparation on page 2) |  |  |  |
| Control                             | Silver 2 vials 4 vi |                                 |                                 | Reconstitute with the volume of standard diluent indicated on the vial. (See Reagents Preparation on page 2) |  |  |  |
| Standard Diluent Buffer             | Black               | 1 vial                          | 1 vial                          | (25 ml) 10X concentrate. Dilute in distilled Water.  |  |  |  |
| Biotinylated anti-CD138             | Red                 | 1 vial                          | 2 vials                         | (0.4 ml) Dilute in biotinylated antibody diluent   |  |  |  |
| Biotinylated Antibody Diluent       | Red                 | 1 vial (7.5 ml)                 | 1 vial (13 ml)                  | Ready-to-use   |  |  |  |
| Streptavidin-HRP                    |                     | 2 vials                         | 4 vials                         | (5 μl) 0.5ml of HRP-Diluent before further dilutions   |  |  |  |
| HRP Diluent                         | Red                 | 1 vial                          | 1 vial                          | (23 ml) Ready-to-use   |  |  |  |
| Washing Buffer                      | White               | 1 vial                          | 2 vials                         | (10 ml) 200X concentrate. Dilute in distilled Water  |  |  |  |
| Chromogen TMB:                      |                     | 1 vial (11 ml)                  | 1 vial (24 ml)                  | Ready-to-use   |  |  |  |
| H2SO4 : Stop Reagent                | Black               | 1 vial                          | 2 vials                         | (11 ml) Ready-to-use   |  |  |  |

# MATERIAL REQUIRED BUT NOT PROVIDED

- \* Distilled water.
- \* Pipettes: 10 μl, 50 μl, 100 μl, 200 μl and 1000 μl.
- \* Vortex mixer and magnetic stirrer.

#### SAFETY

- \* For research use only.
- \* The human blood components included in this kit have been tested and found non reactive for HBsAg and anti-HIV. Nevertheless, no known method can offer complete assurance that human blood derivatives will not transmit hepatitis, AIDS or other infections. Therefore, handling of reagents, serum or plasma specimens should be in accordance with local safety procedures, e.g. CDC/NIH Health manual: "Biosafety in Microbiological and Biomedical Laboratories" 1984.
  - \* Avoid any skin contact with H<sub>2</sub>SO<sub>4</sub> and TMB. In case of contact, wash thoroughly with water.
  - \* Do not eat, drink, smoke or apply cosmetics where kit reagents are used.
  - \* Do not pipette by mouth.

# PROCEDURAL NOTES/LAB. QUALITY CONTROL

Issue 3 16 January 2004 Page 2 / 5

1. When not in use, kit components should be stored refrigerated or frozen as indicated on vials or bottles labels. All reagents should be warmed to room temperature before use. Lyophilized standards and controls should be discarded after use.

- 2. Once the desired number of strips has been removed, immediately reseal the bag to protect the remaining strips from deterioration.
- 3. Cover or cap all reagents when not in use.
- 4. Do not mix or interchange reagents between different lots.
- 5. Do not use reagents beyond the expiration date of the kit.
- 6. Use a clean disposable plastic pipette tip for each reagent, standard, or specimen addition in order to avoid cross-contamination; for the dispensing of H<sub>2</sub>SO<sub>4</sub> and substrate solution, avoid pipettes with metal parts.
- 7. Use a clean plastic container to prepare the washing solution.
- 8. Thoroughly mix the reagents and samples before use by agitation or swirling.
- 9. All residual washing liquid must be drained from the wells by efficient aspiration or by decantation followed by tapping the plate forcefully on absorbent paper. Never insert absorbent paper directly into the wells.
- 10. The TMB solution is light sensitive. Avoid prolonged exposure to light. Also, avoid contact of the TMB solution with metal to prevent colour development. Warning TMB is toxic avoid direct contact with hands. Dispose off properly.
- 11. If a dark blue colour develops within a few minutes after preparation, this indicates that the TMB solution has been contaminated and must be discarded. Read absorbances within 1 hour after completion of the assay.
- 12. When pipetting reagents, maintain a consistent order of addition from well-to-well. This will ensure equal incubation times for all wells.
- 13. Respect incubation times described in the assay procedure.
- 14. Dispense the TMB solution within 15 min. following the washing of the microtiter plate.

#### SPECIMEN COLLECTION, PROCESSING AND STORAGE

Cell culture supernatants- Remove particulates and aggregates by spinning at approximately 1000 x g for 10 min.

**Serum**–Avoid any inintentional stimulation of the cells by the procedure. Use pyrogen/endotoxin free collecting tubes. Serum should be removed rapidly and carefully from the red cells after clothing. For that, after clothing, centrifuge at approximately 1000 x g for 10 min and remove serum.

Plasma-EDTA, citrate and heparin plasma can be assayed. Spin samples at 1000 x g for 30 min to remove particulates. Harvest plasma.

**Storage**-If not analyzed shortly after collection, samples should be aliquoted (250-500µl) to avoid freeze-thaw cycles and stored frozen at – 70°C. Avoid multiple freeze-thaw cycles of frozen specimens.

When possible, avoid use of badly hemolyzed or lipemic sera. If large amounts of particles are present, this should be removed prior to assay by centrifugation or filtration.

**Recommendation**: Do not thaw by heating at 37°C or 56°C. Thaw at room temperature and make sure that sample is completely thawed and homogeneous before assaying

## **PREPARATION OF REAGENTS**

## Standard buffer diluent10X concentrate

Dilute 10 times with distilled water before use.

#### **Standards**

Standard have to be reconstituted with the volume of standard buffer diluent indicated on the vial. This reconstitution produces a stock solution of 256 ng/ml CD138. Allow standard to stand for 5 minutes with gentle swirling prior to making dilutions. Serial dilutions of standard must be made before each assays and cannot be stored.

#### **Controls**

Control have to be reconstituted with the volume of standard buffer diluent indicated on the vial. Reconstitution of the freeze-dried material with the indicated volume, will give a solution for which the CD138 concentration is stated on the vial. Allow control to stand for 5 minutes with gentle swirling prior to distribute in control wells. Do not store after use.

#### Human serum samples

Human serum samples from healthy donors have to be tested neat.

## Dilution of biotinylated anti-CD138

Preparation immediately before use is recommended. Dilute the biotinylated anti-CD138 with the biotinylated antibody diluent in a clean glass vial according to the number of wells to be used. See the next table for volumes to pipette. Extemporaneous preparations are recommended.

| Number of Wells | Biotinylated  | Biotinylated          |  |  |  |
|-----------------|---------------|-----------------------|--|--|--|
| used            | Antibody (µl) | Antibody Diluent (µl) |  |  |  |
| 16              | 40            | 1060                  |  |  |  |
| 24              | 60            | 1590                  |  |  |  |
| 32              | 80            | 2120                  |  |  |  |
| 48              | 120           | 3180                  |  |  |  |
| 96              | 240           | 6360                  |  |  |  |

Issue 3 16 January 2004 Page 3 / 5

## **Dilution of Streptavidin-HRP**

Add 0.5 ml of HRP diluent to a 5  $\mu$ l vial of Streptavidin-HRP . DO NOT KEEP THIS DILUTION FOR FURTHER EXPERIMENTS. Dilute immediately before use. Following the number of wells to be used, further dilutions of Streptavidin-HRP should be made with HRP diluent in a clean glass vial : see hereafter the table for volumes to pipette.

| Number of Wells | Streptavidin-HRP(µl) | Strep-HRP Diluent (ml) |  |  |
|-----------------|----------------------|------------------------|--|--|
| 16              | 30                   | 2                      |  |  |
| 24              | 45                   | 3                      |  |  |
| 32              | 60                   | 4                      |  |  |
| 48              | 75                   | 5                      |  |  |
| 96              | 150                  | 10                     |  |  |

Washing Buffer 200X concentrate

Dilute 200 times in distilled water.

#### **ASSAY METHOD**

- a) Before use, mix all reagents thoroughly without making foam.
- b) Determine the number of microwell strips required to test the desired number of samples, plus appropriate number of wells needed for running blanks standards and controls. <u>Each sample</u>, <u>standard</u>, <u>blank</u> and <u>control</u> <u>samples</u> <u>should</u> <u>be assayed</u> <u>in duplicate</u>. Remove sufficient microwell strips from the pouch.
- c) Add 100 µl of appropriate standard diluent (see preparation of reagents) to standard wells B1, B2, C1, C2, D1, D2, E1, E2, F1, F2. Reconstitute standard vial with the appropriate volume as described in the chapter reagents preparation. Pipet 200 µl of standard into wells A1 and A2 (see Plate Scheme below). Transfer 100 µl from A1 and A2 to B1 and B2 wells. Mix the contents by repeated aspirations and ejections. Take care not to scratch the inner surface of microwells. Repeat this procedure from the wells B1, B2 to wells C1, C2 and from wells C1, C2 to D1, D2 and so on creating two parallel rows of CD138 standard dilutions ranging from 256 to 8 ng/ml. Discard 100 µl from the content of the last microwells used (F1, F2).
  - Alternatively these dilutions can be done in separate tube and diluted standard pipetted directly into wells.
- d) Add  $100 \,\mu l$  of appropriate standard diluent to the blank wells (G1-G2).
- e) Add 100 µl of sample to sample wells and 100µl of reconstituted control vial to control wells (H1, H2).
- f) Preparation of biotinylated anti-CD138: (see preparation of reagents).
- g) Add 50  $\mu l$  of diluted biotinylated anti-CD138 to all wells.
- h) Cover with a plate cover and incubate for 1 hour at room temperature (  $18^{\circ}\text{C}$   $25^{\circ}\text{C}$  ).
- i) Remove the cover and wash the plate as follows:
  - 1) aspirate the liquid from each well;
  - 2) dispense 0.3 ml of washing solution into each well;
  - 3) aspirate again the content of each well;
  - 4) Repeat steps 2) and 3) two times.
- j) Prepare streptavidin-HRP solution just before use : (see preparation of reagents).
- k) Distribute 100µl of. streptavidin-HRP solution to all wells, including blank wells.
- 1) Cover and incubate 30 min at room temperature.
- m) Remove the cover and empty wells. Wash microwell strips according to step i). Proceed immediately to the next step.
- n) Pipette  $100 \mu l$  of ready-to-use TMB substrate solution into all wells, including the blank wells and incubate in the dark for 12-15 minutes at room temperature. Avoid direct exposure to light by wrapping the plate in aluminium foil.
- o) Incubation time of the substrate solution is usually determined by the ELISA reader performances: many ELISA readers record absorbance only up to 2.0 O.D. The O.D. values of the plate should be monitored and the substrate reaction stopped before positive wells are no longer properly readable (maximum 20 minutes).
- p) The enzyme-substrate reaction is stopped by quickly pipetting  $100 \,\mu l$  of  $H_2SO_4$ : stop reagent into each well, including the blank wells, to completely and uniformly inactivate the enzyme. Results must be red immediately after the addition of  $H_2SO_4$ : stop reagent, or within one hour, if the microwell strips are stored at  $2\text{-}8^{\circ}C$  in the dark.
- q) Read absorbance of each well on a spectrophotometer using 450 nm as the primary wavelength and optionally 620 nm (610 nm to 650 nm is acceptable) as the reference wavelength.


Issue 3 16 January 2004 Page 4 / 5

# SUGGESTED PLATE SCHEME

| Standard Concentrating/mL |       |       | tions Sample wells |   |   |   |   |   |   |    |    |    |
|---------------------------|-------|-------|--------------------|---|---|---|---|---|---|----|----|----|
|                           | 1     | 2     | 3                  | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 |
| Α                         | 256   | 256   |                    |   |   |   |   |   |   |    |    |    |
| В                         | 128   | 128   |                    |   |   |   |   |   |   |    |    |    |
| C                         | 64    | 64    |                    |   |   |   |   |   |   |    |    |    |
| D                         | 32    | 32    |                    |   |   |   |   |   |   |    |    |    |
| E                         | 16    | 16    |                    |   |   |   |   |   |   |    |    |    |
| F                         | 8     | 8     |                    |   |   |   |   |   |   |    |    |    |
| G                         | Blank | Blank |                    |   |   |   |   |   |   |    |    |    |
| Н                         | Ctrl  | Ctrl  |                    |   |   |   |   |   |   |    |    |    |

# **DATA ANALYSIS**

Generate a linear standard curve by plotting the average absorbance on the vertical axis versus the corresponding sCD138 standard concentration on the horizontal axis. The amount of sCD138 in each sample is determined by extrapolating OD values to sCD138 concentrations using the standard curve.



Typical sCD138 standard curve ranging from 8 to 256 ng/mL

# **LIMITATIONS OF THE PROCEDURE**

Do not extrapolate the standard curve beyond the 256 ng/ml standard curve point. The dose-response is non-linear in this region and good accuracy is difficult to obtain. Concentrated samples ( > 256 ng/ml ) have to be diluted with standard diluent or with your own sample buffer. During analysis, multiply results by the appropriate dilution factor.

The influence of various drugs, aberrant sera (hemolyzed, hyperlipidemic, jaundiced) has not been investigated. The rate of degradation of native sCD138 in various matrices has not been investigated.

## PERFORMANCES AND CHARACTERISTICS

## Sensitivity

The minimum detectable dose of sCD138 is less than 2.56 ng/ml. This has been determined by adding 3 standard deviations to the mean optical density obtained when the zero standard was assayed 32 times.

Issue 3 16 January 2004 Page 5 / 5

# **Precision**

## Intra-Assay

#### Inter-Assay

| Sample | n | Mean (ng/mL) | SD  | CV%   | Sample | n | Mean (ng/mL) | SD   | CV%   |
|--------|---|--------------|-----|-------|--------|---|--------------|------|-------|
| A      | 8 | 246          | 3.7 | 1.5 % | A      | 8 | 249          | 2.49 | 1 %   |
| В      | 8 | 32           | 2.4 | 7.6 % | В      | 8 | 35           | 2.38 | 6.8 % |

## Linearity of dilution

A human serum pool containing 256 ng/ml of measured sCD138 was serially diluted in standard buffer diluent over the range of the assay. Linear regression of samples versus the expected concentration yielded a quote slope of 0.99.

# Normal serum values

The average concentration of sCD138 detected in 57 normal human sera is 80+/-43 ng/ml.

# ASSAY PROCEDURE SUMMARY Total procedure length: 1h45mn

Add 100 $\mu$ l of sample or diluted standard or control



Add 50µl of diluted biotinylated Detection antibody to all wells



Incubate 1 hour at room temperature



Wash three times



Add 100µl of streptavidin-HRP to all wells



Incubate 30min at room temperature



Wash three times



 $Add\ 100\ \mu l\ of\ ready-to-use\ TMB$  Protect from light. Let the color develop for 12-15 min.



Add 100 H<sub>2</sub>SO<sub>4</sub>



Read Absorbance at 450 nm